Long-term anabolic therapy in the elderly.
The anabolic agent stanozolol has been used to increase weight and activity in the elderly, but its long-term effect are largely unknown. A double-blind trial of stanozolol against placebo was continued for 12 months. Measuremtnes of weight, fat, fat-free mass, behaviour and activity were made at regular intervals, plus detailed biochemical and haematological profiles. There were no differences between the two groups in respect of weight, fat, fat-free mass and activity levels. There were significant increases in haemoglobin at six and 12 months and packed cell volume at 12 months in the active group. No androgenic side-effect were encountered.
D000203:Activities of Daily Living; D000368:Aged; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005853:Geriatrics; D006400:Hematocrit; D006452:Hemoglobinometry; D006801:Humans; D008134:Long-Term Care; D008297:Male; D014176:Protein Biosynthesis; D012885:Skinfold Thickness; D013197:Stanozolol / Q000627:therapeutic use*
D013197:Stanozolol